Evaluation of antinucleocapsid antibody seropositivity following SARS-CoV-2 infection in vaccinated individuals NIAIDNews SARSCoV2 COVID19 Coronavirus Seropositivity AntinucleopcapsidAntibody
By Suchandrima BhowmikJul 6 2022Reviewed by Aimee Molineux The coronavirus disease 2019 pandemic brought about by severe acute respiratory syndrome coronavirus 2 continues to cause adverse health effects to millions of people globally.
A new study published in the Annals of Internal Medicine journal assessed both placebo and vaccine recipients in the mRNA-1273 phase 3 clinical trial who were infected with SARS-CoV-2 during the blinded, placebo-controlled trial phase. The serum samples were collected from all the participants and assayed for the presence of anti-N Abs 5 months post-enrollment.
Information on the severity of symptoms, oxygen saturation, and body temperature was collected for 14 days via telemedicine. The detection of anti-N Abs was carried out with the help of the Elecsys Anti-SARS-CoV-2 immunoassay. The anti-N seropositivity at the PDV for COVID-19 positive participants at an illness visit was found to be 93.4% in placebo recipients and 40.4% in vaccine recipients. Anti-N seropositivity at the PDV was not found to be associated with days between PDV and illness or age, sex, race, body mass index, and risk of severe COVID-19 in both placebo and vaccine recipients. However, it was positively associated with days between illness and second vaccination in the case of vaccine recipients.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Next-generation SARS-CoV-2 nucleocapsid-based vaccines may provide optimal protection against infectionNext-generation SARS-CoV-2 nucleocapsid-based vaccines may provide optimal protection against infection EpicentRx SARSCoV2 COVID19 Nucleocapsid Vaccine Vaccination
Consulte Mais informação »
Vitamin D protects against H1N1 and SARS-CoV-2 infection in miceVitamin D protects against H1N1 and SARS-CoV-2 infection in mice Coronavirus Disease COVID H1N1 SARSCoV2 VitaminD biorxivpreprint
Consulte Mais informação »
SARS-CoV-2 infection of lung endothelial cells and pulmonary capillary microthrombosisSARS-CoV-2 infection of lung endothelial cells and pulmonary capillary microthrombosis uniklinik_hd SARSCoV2 COVID19 PulmonaryCapillaryMicrothrombosis LungEndothelialCells
Consulte Mais informação »
Impact of SARS-CoV-2 infection on menstrual cycleImpact of SARS-CoV-2 infection on menstrual cycle SARSCoV2 COVID19 MenstrualCycle MenstrualIrregularities
Consulte Mais informação »
How does hybrid immunity shape humoral immune response to SARS-CoV-2?In a recent study posted to the medRxiv* preprint server, researchers illustrated that hybrid severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunity widens effective humoral signatures of SARS-CoV-2 vaccinations.
Consulte Mais informação »
Intrahost genetic diversity and evolution of the SARS-CoV-2 B.1.517 lineage during chronic infection of an immunocompromised individualIntrahost genetic diversity and evolution of the SARS-CoV-2 B.1.517 lineage during chronic infection of an immunocompromised individual medrxivpreprint YaleSPH Sydney_Uni UNC infection genetics evolution COVID19 coronavirus covid
Consulte Mais informação »